Mitochondria-targeted polymer-celastrol conjugate with enhanced anticancer efficacy

Area of Science:

• Biomaterials Science
• Nanotechnology
• Pharmacology

Background:

• Celastrol, a triterpene from traditional Chinese medicine, exhibits anticancer properties.
• Poor solubility, short half-life, and toxicity limit celastrol's in vivo application.
• A stable drug delivery system is crucial for effective celastrol cancer therapy.

Purpose of the Study:

• To develop a novel nanoparticle delivery system for celastrol.
• To enhance celastrol's pharmacokinetic profile and targeting capabilities.
• To improve celastrol's anticancer efficacy and reduce systemic toxicity.

Main Methods:

• Synthesized a block copolymer: poly(2-(N-oxide-N,N-dimethylamino)ethyl methacrylate)-block-poly(2-hydroxyethyl methacrylate) (OPDMA-HEMA).
• Created amphiphilic polymer-celastrol conjugates that self-assemble into nanoparticles.
• Evaluated nanoparticle pharmacokinetics, mitochondria targeting, and induction of immunogenic cell death in vitro and in vivo.

Main Results:

• OPDMA-HEMA nanoparticles effectively encapsulated celastrol.
• The nanoparticles demonstrated improved plasma half-life and efficient mitochondria targeting.
• Celastrol-loaded nanoparticles significantly enhanced immunogenic cell death and in vivo therapeutic effects.

Conclusions:

• Mitochondria-targeted OPDMA-HEMA polymer-celastrol nanoparticles overcome celastrol's limitations.
• This delivery system potentiates celastrol's anticancer activity.
• The conjugate shows promise for advanced celastrol-based cancer treatment.